Advertisement

Organisation › Details
Sound Bioventures (Group)
Sound Bioventures is a clinical stage Biotherapeutics focused venture fund, that with a strong foundation in the Nordic biotech ecosystem will invest in EU, UK and USA. The fund will seek opportunities addressing significant unmet medical needs for new therapies. Sound Bioventures is founded by a team of experienced life science investors, and backed by a strong investor syndicate comprising Novo Holdings, Saminvest, Vækstfonden, the European Investment Fund, Ramsbury Invest and the founders. Sound Bioventures Fund I AB is a registered alternative investment fund, under the Swedish Alternative Investment Funds Managers Act. *
![]() |
Start | 2022-01-04 existent |
![]() |
Industry | fund, biotech / life sciences |
Industry 2 | BIOTECH | |
![]() |
Person | Kördel, Johan (Sound Bioventures 202201 Founding Partner before Pharmacia + Biovitrum + Lundbeckfonden Ventures) |
Person 2 | Mukhopadhyay, Bibhash (Sound Bioventures 202201 Founding Partner before Pivotal Life Sciences + NEA + AstraZeneca + JnJ) | |
![]() |
Region | Malmö |
Country | Sweden | |
Street | 41 Per Albin Hanssons väg Medeon Science Park | |
City | 20521 Malmö | |
Address record changed: 2022-01-07 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Sound Bioventures Management AB. (1/4/22). "Press Release: Sound Bioventures Raises € 110 Million for New Biotherapeutics Venture Fund". Malmö & Copenhagen. | ||
Record changed: 2024-02-12 |
Advertisement

More documents for Sound Bioventures (Group)
- [1] Theolytics Ltd.. (4/17/24). "Press Release: Theolytics Successfully Closes Latest Financing Raising Total of £19M ($24.5M) and Welcomes Sound Bioventures as New Investor". Oxford....
- [2] VarmX B.V.. (5/25/23). "Press Release: VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trial". Leiden....
- [3] Teitur Trophics ApS. (3/14/23). "Press Release: Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases". Aarhus....
- [4] Artax Biopharma, Inc.. (5/11/22). "Press Release: Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases". Cambridge, MA....
- [5] Sound Bioventures Management AB. (1/4/22). "Press Release: Sound Bioventures Raises € 110 Million for New Biotherapeutics Venture Fund". Malmö & Copenhagen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top